Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Condition:   Platinum-resistant Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Drug: Afuresertib
Sponsor:   Laekna Limited
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 16, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments